QUESTIONS
Ipamorelin: the questions people actually ask
Risks first. Then mechanism, the stack, the half-life. Direct answers, cited where the claim is quantitative.
What are the risks of ipamorelin?
The main risk is the unknown: no long-term human safety data exists. The only human efficacy trial (n=114, up to 7 days IV) failed its endpoint but showed no ipamorelin-specific safety signal in that short window [3]. Cited cautions are mechanistic — GH-axis effects on IGF-1, glucose, and fluid, plus a class-level cardiac signal from a related agonist [6]. Research-grade material is also of unverified purity.
What are the downsides of ipamorelin?
The biggest downside is that the evidence is thin and largely negative: ipamorelin is unapproved, and its one human efficacy trial missed its primary endpoint (25.3 h vs 32.6 h placebo, p=0.15) [3]. No Phase 3 was run, no long-term safety database exists, and the popular CJC-1295 stack has never been tested as a combination. Marketing far outpaces the data.
Does ipamorelin cause cancer?
No ipamorelin study has reported cancer, and no carcinogenicity trial exists in humans. The concern is theoretical and mechanistic: GH raises IGF-1, a growth factor that promotes cell proliferation [1][4]. Chronically raising GH-pulse amplitude could in theory accelerate growth in a pre-existing tumor — which is why active or recent malignancy is listed as a caution. It is a mechanism-based caution, not an observed finding.
What are the side effects of CJC-1295 and ipamorelin?
Community-reported side effects (anecdotal, not trial data) include a warm facial flush after injecting, mild transient water retention, increased hunger, tingling in the extremities, dizziness, and injection-site irritation. The cited safety cautions concern the GH-axis: glucose effects, fluid retention, and a class-level cardiac signal from a related ghrelin-receptor agonist [6]. No trial has measured the combination's safety in humans.
Does ipamorelin affect cortisol or prolactin?
Minimally — that is its defining feature. In its founding characterization, ipamorelin released GH potently in rats and swine yet did not raise ACTH, cortisol, or prolactin above baseline even at doses more than 200-fold above its GH ED50 [1]. This selectivity is what distinguishes it from older peptides like GHRP-6 and GHRP-2, which do raise those hormones.
What is ipamorelin?
Ipamorelin is a synthetic pentapeptide (five amino acids: Aib-His-D-2-Nal-D-Phe-Lys-NH2) that selectively activates the ghrelin receptor (GHS-R1a) to trigger a pulse of growth hormone [1]. Developed by Novo Nordisk in the 1990s, it was the first highly GH-selective secretagogue. It is not approved as a drug anywhere and is sold only as a research chemical.
What does ipamorelin do for you?
In studies, ipamorelin triggers a single growth-hormone pulse via the ghrelin receptor, without raising cortisol or prolactin [1]. In rats it produced dose-dependent bone growth [4]; in a 2024 ferret model it reduced chemotherapy-induced weight loss [5]. Human efficacy was tested once, for bowel recovery, and was not demonstrated [3]. Community-reported effects (anecdotal) center on sleep and recovery.
What is ipamorelin peptide?
Ipamorelin peptide is the same compound — a wholly synthetic five-amino-acid chain (C38H49N9O5, ~711.9 Da, CAS 170851-70-4) that mimics ghrelin at the GHS-R1a receptor [1]. The non-natural Aib residue and D-amino acids make it resistant to enzymatic breakdown. "Peptide" simply denotes its chemical class: a short chain of amino acids.
Does ipamorelin reduce belly fat?
No human trial supports a belly-fat claim. In a 2024 ferret study, ipamorelin reduced chemotherapy-induced weight loss by about 24% — a weight-defense effect, not fat loss [5]. Community accounts (anecdotal) describe a gradual leaner appearance over weeks five to twelve, confounded by concurrent diet and training. There is no controlled human fat-loss evidence.
Why is ipamorelin being discontinued?
Ipamorelin was never a marketed drug to discontinue. Its only Phase 2 trial (postoperative ileus) failed its primary endpoint and no further development followed [3]. Separately, in 2024 the FDA removed ipamorelin acetate from Category 2 of the interim 503A bulk-substances list and reviewed it at the October 2024 PCAC meeting, restricting compounding-pharmacy access — which is the likely source of "discontinued" talk.
What does CJC-1295 and ipamorelin do?
They are studied together to amplify GH release: CJC-1295 is a GHRH analog and ipamorelin a ghrelin-receptor agonist, acting through complementary pathways [8][11]. A 2026 review reports the combination improved muscle tetanic tension in a mouse model, while stating the evidence is limited to animal studies [15]. No human outcome trial of the combination exists.
Does ipamorelin increase IGF-1?
Not consistently in short studies. Ipamorelin triggers GH, which can raise hepatic IGF-1 over time — but in a 15-day rat bone-growth study, dose-dependent bone growth occurred with no measured change in total IGF-1 [4], pointing to a partly local, pulse-driven effect. In diabetic mice, IGF-I was actually suppressed alongside GH hypersecretion [7]. Context-dependent, not guaranteed.
How does CJC-1295 ipamorelin work?
The two hit different receptors. Ipamorelin activates the ghrelin receptor (GHS-R1a) on pituitary GH cells; CJC-1295 activates the separate GHRH receptor [1]. Because GHRPs stay partly active under conditions that suppress GHRH alone, combining the two produces additive, somatostatin-resistant GH release [9][11]. That complementary mechanism is the rationale for the pairing.
How much CJC-1295 ipamorelin should I take?
There is no validated human dose, and this site gives none. Community stack protocols have no peer-reviewed human dosing basis and are anecdotal [3]. The pharmacological rationale for co-administering a GHRP and a GHRH analog is documented [9][11], but a tested human dose for the combination — for any outcome — does not exist in the literature.
Does CJC-1295 ipamorelin work?
Only animal evidence exists for the combination. A 2026 narrative review reports CJC-1295 + ipamorelin improved maximum muscle tetanic tension in a murine glucocorticoid-induced muscle-loss model, while stating the evidence is limited to animal studies [15]. No controlled human trial has tested whether the combination works for any outcome.
How to reconstitute CJC-1295 ipamorelin 5mg?
This site does not provide a reconstitution or dosing protocol. In general research-handling terms, ipamorelin is supplied as a lyophilized (freeze-dried) powder and reconstituted with bacteriostatic water; as a peptide it degrades with heat and freeze-thaw, and solution is typically refrigerated. These are handling observations, not clinical preparation instructions, and no per-person dose is implied [2].
How long does ipamorelin stay in your system?
The terminal half-life in humans is approximately 2 hours after IV dosing, so the parent peptide is largely cleared within about 10 hours (roughly five half-lives) [2]. The GH pulse it triggers is shorter still, peaking near 40 minutes. Detection by anti-doping labs can extend beyond the plasma half-life, because they target metabolites. Full detail is on the half-life page.
Does ipamorelin make you hungry?
It can. Ipamorelin acts on the ghrelin receptor — the same receptor the natural hunger hormone uses — so increased appetite after dosing is mechanistically expected and is an occasionally-reported community effect [14]. Reports describe it as milder than with GHRP-6. In diabetic mice, GH hypersecretion followed dosing [7], but appetite specifically is a class-level ghrelin-agonist effect.
Will I gain weight on ipamorelin?
No controlled human data answers this. Ipamorelin showed GH-independent stimulation of fat mass and leptin in mice over two weeks [13], and a class-level appetite-driving effect [14], so weight change is biologically plausible. In a 2024 ferret cachexia model it defended body weight against chemotherapy loss [5]. Direction in healthy humans is uncharacterized; this is not a weight-management compound with human evidence.
Does ipamorelin increase appetite?
Yes, by mechanism. As a ghrelin-receptor (GHS-R1a) agonist, ipamorelin engages the same hypothalamic appetite circuitry that drives feeding [14]. Increased hunger in the hours after injection is an occasionally-reported community effect, described as milder than with less selective GHRPs. The appetite effect is a class property of ghrelin agonists, not eliminated by ipamorelin's GH selectivity.
What does ipamorelin peptide do?
Ipamorelin peptide selectively triggers a growth-hormone pulse through the ghrelin receptor, without raising cortisol or prolactin [1]. In rats it drove dose-dependent bone growth [4]; in a ferret model it reduced chemotherapy weight loss [5]. Its one human efficacy trial, for bowel recovery, was negative [3]. Community reports (anecdotal) center on sleep, recovery, and a post-injection flush.
How long does it take for ipamorelin to work?
The GH response is fast: a single pulse peaking near 40 minutes after dosing, then subsiding within hours, on a ~2-hour half-life [2]. That is the measurable pharmacodynamic effect. Community-reported subjective effects like deeper sleep are described as appearing over one to two weeks, but those are anecdotal and not measured outcomes [2].